Low-level Laser Therapy in Patients With Chronic Fibromyalgia
|Chronic Pain||Device: Sham Phoenix Laser Treatment Device: Active Phoenix Laser Treatment|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Outcomes Assessor
Primary Purpose: Treatment
|Official Title:||A Prospective, Randomized, Double-blind, Sham-controlled Study of the Low-level Phoenix Thera-lase 42 Watt Laser in Patients With Chronic Fibromyalgia|
- Symptom Impact Questionnaire [ Time Frame: 8 weeks ]
- 36-item Short Form Survey (SF-36) for Quality of Life [ Time Frame: 8 weeks ]
- Global Rating of Change Scale [ Time Frame: 8 weeks ]
- Medication Usage Scale [ Time Frame: 8 weeks ]
- Algometry to assess pain pressure threshold [ Time Frame: 8 weeks ]
- Accelerometry to assess spinal range of motion [ Time Frame: 8 weeks ]
|Study Start Date:||October 2016|
|Estimated Study Completion Date:||October 2017|
|Estimated Primary Completion Date:||May 2017 (Final data collection date for primary outcome measure)|
Sham Comparator: Sham Phoenix Laser Treatment
Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
Device: Sham Phoenix Laser Treatment
Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
Active Comparator: Active Phoenix Laser Treatment
Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
Device: Active Phoenix Laser Treatment
The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
Fifty consenting participants with long-standing fibromyalgia (> 3 mo duration) will be randomized to one of two treatment groups (n=25 per group) according to a computer generated randomization table. Group 1 will be the 'sham' control group and Group 2 will be the 'active' laser treatment group. The study will be conducted in a double-blind fashion using a standard 42 watt Class IV laser which has a switch at the back of the device which allows the laser to operate in the 'inactive' mode despite giving the operator and patients the appearance of being active (e.g., generates skin warmth and a red beam of light). Treatment will be administered three times/week for three weeks. Data will be collected across the 3-week intervention and one week after completion of the intervention. Data will be analyzed with appropriate statistical methods.
The following outcome measures will be collected at baseline: (1)Standardized SF-36 questionnaire; (2) Symptom Impact Questionnaire; (3) current analgesic medication usage; (4) pressure-pain threshold testing over tender points; and (5) spinal range of motion with an inclinometer and accelerometer. Outcome measures (2) and (3) will be re-assessed during the treatment phase at the end of weeks 1, 2 and 3. At 1 week and 1 month after the last laser/sham treatment session, all baseline assessments will be repeated, in addition to a global rating of change scale. Any patient who reports any harm from the laser/sham treatments on the helpfulness scale will be queried for specific harm details.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02948634
|Contact: Jason Zafereo, PT, PhDfirstname.lastname@example.org|
|United States, Texas|
|McDermott Pain Management Clinic||Recruiting|
|Dallas, Texas, United States, 75390|
|Contact: Jason Zafereo, PT, PhD 214-648-1002 email@example.com|
|Principal Investigator: Ross Querry, PT, PhD|
|Principal Investigator:||Jason Zafereo, PT, PhD||UT Southwestern|